Review

anti-myosin heavy chain type i (Developmental Studies Hybridoma Bank)

Developmental Studies Hybridoma Bank is a verified supplier

Developmental Studies Hybridoma Bank manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Developmental Studies Hybridoma Bank anti-myosin heavy chain type i
Anti Myosin Heavy Chain Type I, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 96/100, based on 642 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myosin+heavy+chain+type+i/anti-Myosin+heavy+chain+Type+I/custom%40ba%2Ed5%4041819653
Average 96 stars, based on 642 article reviews

anti-myosin heavy chain type i - by Bioz Stars, 2026-09

96/100 stars

Images

Incubation:

Article Title: Increased muscle satellite cell content and preserved telomere length in response to combined exercise training in patients with FSHD
Article Snippet: The next day, sections were washed 2 × 5 min in phosphate-buffered saline (PBS) and incubated with a biotinylated secondary antibody (BA-2000; Vector Laboratories, Newark, CA, USA; dilution 1:200), followed by Vectastain ABC reagent (PK6100; Vector Laboratories) and the DAB substrate kit (SK-4105; Vector Laboratories). .. Sections were then incubated for 60 min with three antibodies against laminin (D18; dilution 1:100), myosin heavy chain type I (BA-F8; dilution 1:300) and type IIA (SC-71; dilution 1:300) from Developmental Studies Hybridoma Bank (DSHB, Iowa City, IA, USA). .. After washing 2 × 5 min in PBS, fluorescent secondary antibodies were applied for 60 min (Alexa Fluor 488 IgG2A, cat. no. A-21131; Alexa Fluor 488 IgG2B, cat. no. A-21141; and Alexa Fluor 568 IgG1, cat. no. A-21124; all purchased from Invitrogen, Taastrup, Denmark).

Article Title: In vivo mouse model of calcific myonecrosis induced by injury
Article Snippet: .. After blocking with Blocking One Histo (Nacalai Tesque) for 10 min at room temperature (RT), the sections were incubated overnight at 4 °C with the following primary antibodies: anti-NLRP3 (rat monoclonal; R&D Systems, Minneapolis, MN, USA), anti-ASC (rabbit polyclonal; Merck), anti-caspase-1 (rabbit polyclonal; Abcam), laminin (rabbit polyclonal; Merck), myosin heavy chain type I (mouse monoclonal, clone BA-D5; DSHB, Iowa City, IA, USA), myosin heavy chain type IIa (mouse monoclonal, clone SC-71; DSHB), and myosin heavy chain type IIb (mouse monoclonal, clone BF-F3; DSHB). .. Alexa Fluor 488 plus-conjugated anti-rat IgG, Alexa Fluor 594 plus-conjugated anti-rabbit IgG, Alexa Fluor 647-conjugated anti-mouse IgG2b, Alexa Fluor 488-conjugated anti-mouse IgG1 and Alexa Fluor 555-conjugated anti-mouse IgM secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA) were applied for 1 hr at RT.

Article Title: Increased muscle satellite cell content and preserved telomere length in response to combined exercise training in patients with FSHD
Article Snippet: The next day, sections were washed 2 × 5 min in phosphate‐buffered saline (PBS) and incubated with a biotinylated secondary antibody (BA‐2000; Vector Laboratories, Newark, CA, USA; dilution 1:200), followed by Vectastain ABC reagent (PK6100; Vector Laboratories) and the DAB substrate kit (SK‐4105; Vector Laboratories). .. Sections were then incubated for 60 min with three antibodies against laminin (D18; dilution 1:100), myosin heavy chain type I (BA‐F8; dilution 1:300) and type IIA (SC‐71; dilution 1:300) from Developmental Studies Hybridoma Bank (DSHB, Iowa City, IA, USA). .. After washing 2 × 5 min in PBS, fluorescent secondary antibodies were applied for 60 min (Alexa Fluor 488 IgG2A, cat. no. A‐21131; Alexa Fluor 488 IgG2B, cat. no. A‐21141; and Alexa Fluor 568 IgG1, cat. no. A‐21124; all purchased from Invitrogen, Taastrup, Denmark).

Article Title: CSRP3 promotes skeletal muscle remodeling toward aerobic metabolism and enhances exercise endurance through increasing LDHD activity.
Article Snippet: Exercise performance and skeletal muscle homeostasis are influenced by myofiber type composition.. Cysteine and glycine-rich protein 3 (CSRP3) is highly expressed in the oxidative fiber-rich mammalian soleus muscle.. However, the mechanistic basis of CSRP3's involvement in skeletal muscle development and myofiber type specification remains unclear.

Article Title: In vivo mouse model of calcific myonecrosis induced by injury.
Article Snippet: .. After blocking with Blocking One Histo (Nacalai Tesque) for 10 min at room temperature (RT), the sections were incubated overnight PLOS One | https://doi.org/10.1371/journal.pone.0346816 April 22, 2026 4 / 16 at 4 °C with the following primary antibodies: anti-NLRP3 (rat monoclonal; R&D Systems, Minneapolis, MN, USA), antiASC (rabbit polyclonal; Merck), anti-caspase-1 (rabbit polyclonal; Abcam), laminin (rabbit polyclonal; Merck), myosin heavy chain type I (mouse monoclonal, clone BA-D5; DSHB, Iowa City, IA, USA), myosin heavy chain type IIa (mouse monoclonal, clone SC-71; DSHB), and myosin heavy chain type IIb (mouse monoclonal, clone BF-F3; DSHB). .. Alexa Fluor 488 plus-conjugated anti-rat IgG, Alexa Fluor 594 plus-conjugated anti-rabbit IgG, Alexa Fluor 647- conjugated anti-mouse IgG2b, Alexa Fluor 488-conjugated anti-mouse IgG1 and Alexa Fluor 555-conjugated anti-mouse IgM secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA) were applied for 1 hr at RT.

Blocking Assay:

Bioprocessing:

Article Title: Diaphragm hypertrophy and spinal stress response accompany phrenic myelin defects in a murine model of Charcot-Marie-Tooth Disease Type 1E.
Article Snippet: Charcot-Marie-Tooth disease type 1E (CMT1E) is a rare, early-onset dysmyelinating neuropathy linked with point mutations in the peripheral myelin protein 22 (PMP22) gene.. Respiratory problems are known to impact neuropathic patients, yet existing studies have not characterized this pathophysiology in corresponding animal models.. Trembler J (TrJ) mice carry the same Leu16Pro amino acid substitution in the PMP22 protein that is present in families diagnosed with CMT1E.

Image Search Results

(A) Representative magnetic resonance imaging (MRI) of the thigh and quadriceps muscle cross-sectional area (CSA) assessed by MRI (controls: n = 17; HSCT: n = 11). (B) Representative DXA scan and whole-body, and leg, lean mass assessed by DXA (controls: n = 27; HSCT: n = 17). (C) Whole-body bone mineral density and Z-scores assessed by DXA (controls: n = 27; HSCT: n = 17). (D) Isometric maximal voluntary contraction (MVC) measured by dynamometry, presented as Isometric MVC and Specific force (normalized to body weight) (controls: n = 28; HSCT: n = 18). Rate of force development (RFD) was also measured by dynamometry (controls: n = 11; HSCT: n = 7). (E) Physical function assessed using the 30-s chair-stand test, timed up-and-go test, and 6-min walk test (controls: n = 17; HSCT: n = 11). F-K. Data from muscle biopsy immunofluorescence, analyzed by two-way repeated-measures ANOVA with factors Group and Sex. Data are displayed as individual values with mean ± SD. Men are represented by circles, women by squares (controls: n = 26; HSCT: n = 16). (F) Muscle biopsy cross-section stained by immunofluorescence with the basement membrane marker laminin, delineating the muscle fiber borders, and type I myosin heavy chain (MyHC I). The unstained (black) fibers were designated type II fibers. Scale bar = 100 μm. Such images were used to calculate fiber type-specific data for G) fiber type distribution (proportion and relative area), H) shape factor index, I) fiber cross-sectional area (CSA), J) myonuclear content, K) myonuclear domain size. A-E. Data were analyzed with unpaired two-tailed t-tests.

Journal: medRxiv

Article Title: Single-Nucleus to Whole Body Phenotyping Reveals Neuromuscular Impairment and Preserved Exercise Adaptations in Long-Term Pediatric HSCT Survivors >10 years after treatment

doi: 10.64898/2026.04.24.26351644

Figure Lengend Snippet: (A) Representative magnetic resonance imaging (MRI) of the thigh and quadriceps muscle cross-sectional area (CSA) assessed by MRI (controls: n = 17; HSCT: n = 11). (B) Representative DXA scan and whole-body, and leg, lean mass assessed by DXA (controls: n = 27; HSCT: n = 17). (C) Whole-body bone mineral density and Z-scores assessed by DXA (controls: n = 27; HSCT: n = 17). (D) Isometric maximal voluntary contraction (MVC) measured by dynamometry, presented as Isometric MVC and Specific force (normalized to body weight) (controls: n = 28; HSCT: n = 18). Rate of force development (RFD) was also measured by dynamometry (controls: n = 11; HSCT: n = 7). (E) Physical function assessed using the 30-s chair-stand test, timed up-and-go test, and 6-min walk test (controls: n = 17; HSCT: n = 11). F-K. Data from muscle biopsy immunofluorescence, analyzed by two-way repeated-measures ANOVA with factors Group and Sex. Data are displayed as individual values with mean ± SD. Men are represented by circles, women by squares (controls: n = 26; HSCT: n = 16). (F) Muscle biopsy cross-section stained by immunofluorescence with the basement membrane marker laminin, delineating the muscle fiber borders, and type I myosin heavy chain (MyHC I). The unstained (black) fibers were designated type II fibers. Scale bar = 100 μm. Such images were used to calculate fiber type-specific data for G) fiber type distribution (proportion and relative area), H) shape factor index, I) fiber cross-sectional area (CSA), J) myonuclear content, K) myonuclear domain size. A-E. Data were analyzed with unpaired two-tailed t-tests.

Article Snippet: For fiber type–specific morphology and fiber type distribution, sections were stained with MyHC I (BA.D5; DSHB) and laminin (L9393; Sigma-Aldrich).

Techniques: Magnetic Resonance Imaging, Immunofluorescence, Staining, Membrane, Marker, Two Tailed Test

A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes that were treated during differentiation with various NSAIDs, including aspirin (ASA), indomethacin (INDO), ibuprofen (IBU), celecoxib, and SC-236 at the indicated concentrations. Cells were stained for myosin heavy chain (MyHC, green), myogenin (MyoG, red), and DAPI (nuclei, blue). B: Representative immunofluorescence images of day 3 post-differentiation C2C12 myotubes treated with doses of INDO ranging from 6.25 µM to 400 µM. C-E : Quantitative analysis of INDO-treated cells showing a dose-dependent decrease in DAPI + cell density ( C ), differentiation index (%) ( D ), and myotube area (%) ( E ). F: Representative images of ASA-treated myotubes ranging from 62.5 µM to 4 mM. H–J: Quantification of DAPI + cell density ( H ), differentiation index (%) ( I ), and myotube area (%) ( J ) in C2C12 cells receiving ASA treatment. K: Representative images comparing the effects of ASA (2 mM), INDO (200 µM), and the combination of INDO + ASA on C2C12 myotube morphology. L-N: Statistical comparison of cell density ( L ), differentiation index (%) ( M ), and myotube area (%) ( N ) across vehicle and treatment groups. Data are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Holm-Šídák post hoc tests. *, **, ***, and **** denotes p<0.05, p<0.01, p<0.001, and p<0.0001 between indicated groups, respectively. # denotes p<0.05 difference between ASA and vehicle groups.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF-F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD206 (Bio-Rad, MCA2387, 1:50), and laminin (Abcam, ab7463, 1:200).

Techniques: Immunofluorescence, Staining, Comparison

Journal: bioRxiv

Article Title: Aspirin hastens resolution of skeletal muscle inflammation and promotes recovery of muscle strength following acute injury

doi: 10.64898/2026.04.21.719989

Figure Lengend Snippet: A: Force-frequency curves showing maximal isometric tetanic force generated by the TA muscle in situ at day 14 post-injury. B: Total area under the force-frequency curve (absolute muscle strength). C-D: Specific force-frequency curves ( C ) and specific force-frequency area under the curve ( D ) (relative muscle strength) normalized to muscle size. E: Representative histological and immunofluorescence images of muscle cross-sections. Top: H & E staining; Middle: Actin (red), DAPI (blue), and Laminin (LAM, white); Bottom: Fiber type staining for type I (blue), type IIA (green), type IIX (black), and type IIX (red), and laminin (white). F-H: Quantification of regenerative maturation markers including the percentage of centrally nucleated myofibers ( F ), fibers with ≥2 central nuclei ( G ), and fibers with ≥3 central nuclei ( H ). I-J: Mean myofiber cross-sectional area (CSA) ( I ) and muscle fiber type profile (I, IIA, IIX, IIB) ( J ). Data are presented as mean ± SEM. For force-frequency curves statistical significance was determined by two-way ANOVA followed by Holm-Šídák post hoc tests. * denotes p<0.05 vs. uninjured control mice (CON), # denotes p<0.05 vs. injured mice receiving VEH, and $ denotes p<0.05 vs. injured mice receiving ASA. For bar graphs, different letters indicate significant differences (p<0.05) by one-way ANOVA with Holm-Šídák post hoc tests.

Techniques: Generated, In Situ, Immunofluorescence, Staining, Control

Skeletal muscle size and force characterization of tamoxifen‐inducible skeletal muscle‐specific Unc45b knockout mice. (A) Quantification of UNC45B expression in gastrocnemius muscle, soleus muscle, plantaris muscle, diaphragm, and heart in Unc45b flox/flox mice and ACTA1‐MerCreMer; Unc45b flox/flox mouse 8 weeks after tamoxifen injection. (B) Representative western blots for UNC45B. (C) UNC45B expression. (D) Body weight. Relative mass of the (E) gastrocnemius and (F) soleus muscles, expressed as a ratio to body weight. (G) Grip strength normalized to body weight. (H) Plantar flexor torque. (I) Plantar flexor torque normalized to triceps surae muscle mass. (J) Representative images of gastrocnemius muscle. Scale bar set to 50 μm. CSA of (K) type I, (L) type IIa, (M) type IIx, and (N) type IIb fibers in gastrocnemius muscle. (O) Representative images of soleus muscle. Scale bar set to 50 μm. CSA of (P) type I, (Q) type IIa, (R) type IIx, and (S) type IIb fibers in soleus muscle. (T) Representative western blots. (U) Myosin expression. Data are shown as means and individual values ± standard error (2 weeks, n = 6; 4 weeks, n = 6; 8 weeks, n = 6). Different letters indicate significant differences between groups. BW, body weight; fCSA, fiber cross‐sectional area; GAS, gastrocnemius; SOL, soleus; Unc45b imKO, inducible skeletal muscle‐specific Unc45b knockout.

Journal: Aging Cell

Article Title: UNC45B Reduction With Aging: A Myofiber‐Intrinsic Promoting Factor for Sarcopenia

doi: 10.1111/acel.70502

Figure Lengend Snippet: Skeletal muscle size and force characterization of tamoxifen‐inducible skeletal muscle‐specific Unc45b knockout mice. (A) Quantification of UNC45B expression in gastrocnemius muscle, soleus muscle, plantaris muscle, diaphragm, and heart in Unc45b flox/flox mice and ACTA1‐MerCreMer; Unc45b flox/flox mouse 8 weeks after tamoxifen injection. (B) Representative western blots for UNC45B. (C) UNC45B expression. (D) Body weight. Relative mass of the (E) gastrocnemius and (F) soleus muscles, expressed as a ratio to body weight. (G) Grip strength normalized to body weight. (H) Plantar flexor torque. (I) Plantar flexor torque normalized to triceps surae muscle mass. (J) Representative images of gastrocnemius muscle. Scale bar set to 50 μm. CSA of (K) type I, (L) type IIa, (M) type IIx, and (N) type IIb fibers in gastrocnemius muscle. (O) Representative images of soleus muscle. Scale bar set to 50 μm. CSA of (P) type I, (Q) type IIa, (R) type IIx, and (S) type IIb fibers in soleus muscle. (T) Representative western blots. (U) Myosin expression. Data are shown as means and individual values ± standard error (2 weeks, n = 6; 4 weeks, n = 6; 8 weeks, n = 6). Different letters indicate significant differences between groups. BW, body weight; fCSA, fiber cross‐sectional area; GAS, gastrocnemius; SOL, soleus; Unc45b imKO, inducible skeletal muscle‐specific Unc45b knockout.

Article Snippet: The primary antibodies used in this study were as follows: mouse anti‐myosin heavy chain type I (1:50, BA‐D5, DSHB, IA, USA), anti‐myosin heavy chain type IIa (1:200, SC‐71, DSHB), anti‐myosin heavy chain type IIb (1:100, BF‐F3, DSHB), anti‐Laminin (1:200, L9393, Sigma‐Aldrich), anti‐MYH1 (1:200, M4276, Sigma‐Aldrich), and anti‐Laminin‐2 (1:400, L0663, Sigma‐Aldrich).

Techniques: Knock-Out, Expressing, Injection, Western Blot, Muscles